Nevirapină Accord (Nevirapine)

Nevirapine, the active ingredient in Nevirapină Accord, is a Non‑nucleoside reverse transcriptase inhibitor (NNRTI) presented as an oral tablet for oral use. It is used in the management of HIV‑1 infection in adults and adolescents.

GNH USA supplies Nevirapină Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nevirapină Accord is a non‑nucleoside reverse transcriptase inhibitor indicated for HIV‑1 infection and related therapeutic strategies.

- HIV‑1 infection (treatment): reduces viral replication when used as part of combination antiretroviral therapy. - Mother‑to‑child transmission prevention: administered to pregnant women to lower the risk of vertical HIV transmission. - Pediatric HIV‑1 infection (≥2 kg): used in combination regimens for children meeting weight criteria.

Nevirapină Accord may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Rash: mild to moderate skin eruption. - Nausea: occasional gastrointestinal discomfort. - Headache: transient cranial pain. - Fatigue: general feeling of tiredness. - Diarrhea: loose stools, usually self‑limiting. - Elevated liver enzymes: mild increase in hepatic transaminases.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe mucocutaneous reaction requiring immediate medical attention. - Hepatotoxicity: significant liver injury, potentially leading to jaundice or hepatitis. - Severe rash or hypersensitivity: may progress to toxic epidermal necrolysis. - Hematologic abnormalities: rare cases of anemia or neutropenia.

Before initiating therapy with Nevirapină Accord, consider the following precautions.

- Hepatic monitoring: assess liver function tests prior to start and periodically during treatment. - Dermatologic assessment: examine skin for rash; discontinue if severe. - Drug resistance: avoid monotherapy to prevent emergence of resistant HIV strains. - Pregnancy considerations: evaluate risk‑benefit ratio; consult specialist. - Breastfeeding: discuss potential infant exposure with healthcare provider. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and direct sunlight.

Nevirapină Accord can interact with several medications, affecting efficacy or safety.

Major Interactions (Avoid): - Rifampicin: induces metabolism, markedly reducing nevirapine levels. - St. John’s wort: strong enzyme inducer, may lower drug exposure. - Protease inhibitors (e.g., ritonavir): can increase nevirapine concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., ketoconazole): may increase nevirapine levels modestly. - Warfarin: potential alteration of anticoagulant effect; monitor INR. - Oral contraceptives: nevirapine may reduce hormonal efficacy; advise additional contraceptive measures.